摘要
糖尿病肾病是糖尿病最常见的微血管并发症之一,是导致终末期肾病的常见原因。钠-葡萄糖协同转运蛋白2抑制剂作为一种新型降糖药,其可有效降低血糖,还可改善肾高滤过状态、降低血压及尿蛋白、改善肾缺氧、减轻炎症和氧化应激、降低血尿酸、体重及血脂等。本文综述钠-葡萄糖协同转运蛋白2抑制剂及其对糖尿病肾病的保护作用机制。
As one of the most common microvascular complications of diabetes mellitus,diabetic nephropathy(DN)is a common cause of end-stage renal disease(ESRD).Sodium-glucose cotransporter 2(SGLT-2)inhibitor,a new type of hypoglycemic agent,may effectively lower blood glucose,improve renal hyperfiltration,lower blood pressure,reduce urinary protein,improve renal hypoxia,reduce inflammation and oxidative stress,lower serum uric acid,weight and plasma lipids,etc.This review summarized its protective mechanism on DN.
作者
孔令莉
孙源博
王晓莉
任明玉
李桂芹
Kong Ling-li;Sun Yuan-bo;Wang Xiao-li;Ren Ming-yu;Li Gui-qin(The First Clinical Medical College of Mudanjiang Medical University,Mudanjiang 157011,China;Department of Nephrology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Mudanjiang 157011,China)
出处
《临床肾脏病杂志》
2021年第4期338-342,共5页
Journal Of Clinical Nephrology
